Brenda Dickow
About
Brenda Dickow is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Brenda Dickow has authored 20 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Brenda Dickow's work include Prostate Cancer Treatment and Research (9 papers), Renal cell carcinoma treatment (7 papers) and Renal and related cancers (5 papers). Brenda Dickow is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Renal cell carcinoma treatment (7 papers) and Renal and related cancers (5 papers). Brenda Dickow collaborates with scholars based in United States, Netherlands and Italy. Brenda Dickow's co-authors include Ulka N. Vaishampayan, Elisabeth I. Heath, Joseph A. Fontana, Lance K. Heilbrun, Daryn Smith, Patricia Fischer, Alain Ravaud, Patricia Creel, Robert J. Motzer and Dorothy A. White and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.
In The Last Decade
Brenda Dickow
20 papers receiving 442 citations
Peers
Brenda Dickow
Ilya Tsimafeyeu Russia
Begoña Pérez‐Valderrama Spain
Srinivas K. Tantravahi United States
Chukwuemeka Ikpeazu United States
Jindřich Kopecký Czechia
Raffaele Ratta Italy
I. Alex Bowman United States
Laure Hirsch France
Fabio A. Schutz United States
Kuniko Sunami Japan
Citations per year, relative to Brenda Dickow Brenda Dickow (= 1×)
peers
Ilya Tsimafeyeu
Countries citing papers authored by Brenda Dickow
Since
Specialization
Citations
This map shows the geographic impact of Brenda Dickow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brenda Dickow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brenda Dickow more than expected).
Fields of papers citing papers by Brenda Dickow
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brenda Dickow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brenda Dickow. The network helps show where Brenda Dickow may publish in the future.
Co-authorship network of co-authors of Brenda Dickow
This figure shows the co-authorship network connecting the top 25 collaborators of Brenda Dickow. A scholar is included among the top collaborators of Brenda Dickow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brenda Dickow. Brenda Dickow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Heath, Elisabeth I., Archana Thakur, Wei Chen, et al.. (2024). Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer. Cancer Research Communications. 4(7). 1715–1725.
2.
Vaishampayan, Ulka N., Lance K. Heilbrun, Nitin Vaishampayan, et al.. (2023). Phase II Trial of Concurrent Nivolumab and Radiation Therapy for Muscle-Invasive Bladder Cancer of Older or Chemotherapy-Ineligible Patients. International Journal of Radiation Oncology*Biology*Physics. 118(5). 1472–1480.
3.
Vaishampayan, Ulka N., Archana Thakur, Wei Chen, et al.. (2022). Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(1). 122–133.
4.
Vaishampayan, Ulka N., Lance K. Heilbrun, Paul Monk, et al.. (2021). Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open. 4(1). e2034633–e2034633.
5.
Vaishampayan, Ulka N., Lance K. Heilbrun, Dongping Shi, et al.. (2020). 776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]. Annals of Oncology. 31. S596–S596.
6.
Vaishampayan, Ulka N., Harsh Shah, Dongping Shi, et al.. (2020). Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. PubMed. 7(4). 1–7.
7.
Vaishampayan, Ulka N., Jawana M. Lawhorn‐Crews, Lance K. Heilbrun, et al.. (2017). A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer. Molecular Imaging and Biology. 19(6). 810–816.
8.
Jeyakumar, Ghayathri, Seongho Kim, Naresh Bumma, et al.. (2017). Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer. 5(1). 82–82.
9.
Jeyakumar, Ghayathri, Naresh Bumma, Seongho Kim, et al.. (2017). Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers.. Journal of Clinical Oncology. 35(6_suppl). 453–453.
10.
Vaishampayan, Ulka N., Daniel H. Shevrin, Mark N. Stein, et al.. (2015). Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology. 86(6). 1206–1211.
11.
Vaishampayan, Ulka N., et al.. (2013). The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clinical Genitourinary Cancer. 12(2). 124–129.
12.
Vaishampayan, Ulka N., Joseph A. Fontana, Lance K. Heilbrun, et al.. (2013). Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 32(1). 31.e25–31.e33.
13.
Gupta, Sachin, Lance K. Heilbrun, Daryn Smith, et al.. (2011). Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anti-Cancer Drugs. 22(8). 794–800.
14.
Porta, Camillo, Susanne Osanto, Alain Ravaud, et al.. (2011). Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer. 47(9). 1287–1298.
15.
Vaishampayan, Ulka N., Lance K. Heilbrun, Brenda Dickow, et al.. (2011). Phase II trial of combination therapy with intravenous bevacizumab (B), oral satraplatin (S), and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 29(7_suppl). 152–152.
16.
Vaishampayan, Ulka N., Lance K. Heilbrun, Elisabeth I. Heath, et al.. (2009). Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). e16028–e16028.
17.
Gupta, Sachin, Lance K. Heilbrun, David C. Smith, et al.. (2009). Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). Journal of Clinical Oncology. 27(15_suppl). 5108–5108.
18.
Vaishampayan, Ulka N., Shanthi Marur, Lance K. Heilbrun, et al.. (2009). Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer. The Journal of Urology. 182(1). 317–323.
19.
Marur, Shanthi, James F. Eliason, Lance K. Heilbrun, et al.. (2008). Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. Urology. 72(4). 898–902.
20.
Marur, Shanthi, James F. Eliason, Lance K. Heilbrun, et al.. (2007). Phase II trial of oral capecitabine (C) and weekly docetaxel (D) in patients with metastatic androgen independent prostate cancer (AIPC). Journal of Clinical Oncology. 25(18_suppl). 5121–5121.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ilya Tsimafeyeu Breakdown of academic impact, for papers by Begoña Pérez‐Valderrama Breakdown of academic impact, for papers by Srinivas K. Tantravahi Breakdown of academic impact, for papers by Chukwuemeka Ikpeazu Breakdown of academic impact, for papers by Jindřich Kopecký Breakdown of academic impact, for papers by Raffaele Ratta Breakdown of academic impact, for papers by I. Alex Bowman Breakdown of academic impact, for papers by Laure Hirsch Breakdown of academic impact, for papers by Fabio A. Schutz Breakdown of academic impact, for papers by Kuniko Sunami